<SEC-DOCUMENT>0001209191-22-051416.txt : 20220927
<SEC-HEADER>0001209191-22-051416.hdr.sgml : 20220927
<ACCEPTANCE-DATETIME>20220927210040
ACCESSION NUMBER:		0001209191-22-051416
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220925
FILED AS OF DATE:		20220927
DATE AS OF CHANGE:		20220927

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Dunne Michael W.
		CENTRAL INDEX KEY:			0001553593

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38503
		FILM NUMBER:		221272636

	MAIL ADDRESS:	
		STREET 1:		DURATA THERAPEUTICS, INC.
		STREET 2:		89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
		CITY:			MORRISTOWN
		STATE:			NJ
		ZIP:			07960

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Iterum Therapeutics plc
		CENTRAL INDEX KEY:			0001659323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L2
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		FITZWILLIAM COURT, 1ST FLOOR
		STREET 2:		LEESON CLOSE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 YW24
		BUSINESS PHONE:		(872) 225-6077

	MAIL ADDRESS:	
		STREET 1:		FITZWILLIAM COURT, 1ST FLOOR
		STREET 2:		LEESON CLOSE
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 YW24

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Iterum Therapeutics Ltd
		DATE OF NAME CHANGE:	20151124
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-09-25</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001659323</issuerCik>
        <issuerName>Iterum Therapeutics plc</issuerName>
        <issuerTradingSymbol>ITRM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001553593</rptOwnerCik>
            <rptOwnerName>Dunne Michael W.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ITERUM THERAPEUTICS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>FITZWILLIAM COURT, FL. 1, LEESON CLOSE</rptOwnerStreet2>
            <rptOwnerCity>DUBLIN 2</rptOwnerCity>
            <rptOwnerState>L2</rptOwnerState>
            <rptOwnerZipCode></rptOwnerZipCode>
            <rptOwnerStateDescription>IRELAND</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Restricted Share Units</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-09-25</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1779</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1779</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1779</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each restricted share unit (&quot;RSU&quot;) represents the contingent right to receive one ordinary share upon vesting of the RSU.</footnote>
        <footnote id="F2">Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Michael W. Dunne</signatureName>
        <signatureDate>2022-09-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
